Guías clínicas 245 Guía AUGE MINSAL Virus Hepatitis C - A. Soza R. et al. PegIFN/Ribavirin in HCV Genotype-1/ HIV-1 Coinfection (Study C212). 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014; abstract 24. 178.- www.ClinicalTrials.gov. NCT02206932. 179.- David Wyles, Mark S Sulkowski, Joseph J Eron. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/ Ombitasvir and Dasabuvir and Ribavirin 65th Annual Meeting of the American Association for the Study of Liver Diseases .Boston, MA Nov 7-11, 2014. 180.- Anu Osinusi, Kerry Townsend, Amy Nelson and Hepatitis C ERADICATE team. Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston Nov 7-11, 2014. 181.- Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57. 182.- Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10. 183.- Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18: 97-115. 184.- Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, et al. Histopathological features of hepatitis C in renal transplant candidates see comment. Transplantation 2000; 69: 1479-84. 185.- Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-7. 186.- Abbott KC, Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-18. 187.- Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255-61. 188.- Morales JM, Pascual-Capdevila J, Campistol JM, Fernández-Zatarain G, Muñoz MA, Andres A, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63: 1634-9. 189.- Baid S, Pascual M, Williams WW Jr, Tolkoff-Rubin N, Johnson SM, Collins B, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-53. 190.- Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81. 191.- Russo MW, Goldsweig CD, Jacobson IM, Brown RS, Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5. 192.- Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8: 287-92. 193.- Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-21. 194.- Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-5. 195.- Covic A, Maftei ID, Mardare NG, Ionita-Radu F, Totolici C, Tuta L, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006; 19: 794-801. 196.- Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263. 197.- Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-4. 198.- Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferonalpha therapy. Transplantation 1998; 66: 1254-8. 199.- Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-33. 200.- Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol 2008; 103: 2123-34. 201.- van Heeswijk R VA, Boogaerts G, De Paepe E, van Solingen-Ristea R, Garg V, et al. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir. J Hepatol 2011; 54: S492. 202.- Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O’Mara E, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012; 51: 619-28. 203.- Franchini M. Hepatitis C in haemophiliacs. Thromb Haemost 2004; 92: 1259-68. 204.- Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 1999; 179: 1062-9. 205.- Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am J Epidemiol 2007; 165: 1443-53. 206.- Zhang M, Rosenberg PS, Brown DL, Gastroenterol. latinoam 2015; Vol 26, Nº 4: 214-247
gastrolat2015n400006
To see the actual publication please follow the link above